Pro-angiogenic small-diameter tissue-engineered vascular grafts (TEVGs) fabricated from 2-deoxy-D-ribose (2dDR)-incorporated electrospun polycaprolactone (PCL) fibers
Source abstract
Abstract
Abstract Cardiovascular diseases remain the leading cause of global mortality and frequently require surgical interventions such as bypass grafting. Although autologous vessels are considered the gold standard, their limited availability and donor site morbidity necessitate effective synthetic alternatives. However, small-diameter synthetic grafts often fail due to insufficient endothelialization, leading to rapid protein adsorption, thrombosis, intimal hyperplasia, and graft occlusion. This study aimed to develop a pro-angiogenic small-diameter tissue-engineered vascular graft based on electrospun polycaprolactone (PCL) functionalized with 2-deoxy-D-ribose (2dDR), a cost-effective and biologically safe pro-angiogenic molecule. Tubular grafts were fabricated by electrospinning a 15% (w/w) PCL solution prepared in a DCM:DMF (90:10 w/w) solvent mixture, followed by incorporation of 2dDR (66.7 mg g −1 polymer) into the spinning solution. Electrospinning parameters were systematically optimized to obtain uniform bead-free nanofibers. The resulting scaffolds were characterized in terms of fiber morphology, wettability, mechanical properties, release behavior, and in vitro endothelial cell response. Optimized conditions produced fibers with an average diameter of 0.77 ± 0.41 μm. Although incorporation of 2dDR did not change the mean fiber diameter (0.74 ± 0.37 μm), it markedly enhanced scaffold hydrophilicity, reducing the water contact angle from 111.82 ± 5.43° to complete spreading within 30 s. Mechanical testing demonstrated that 2dDR incorporation significantly increased tensile strength and suture retention by approximately 2-fold and 1.4-fold, respectively, without significantly altering elastic modulus or elongation at break. 2dDR release from PCL fibers was observed over 21 d, with concentrations remaining within the pro-angiogenic range of 1–2.5 mM. In vitro cytocompatibility assays demonstrated cell viability above 90%, and alamarBlue analysis indicated increased metabolic activity on 2dDR-loaded scaffolds, particularly on days 4 and 7, while scanning electron microscope observations showed endothelial cell coverage on the luminal surface by day 7 in both scaffold groups. Overall, this proof-of-concept study demonstrates the in vitro feasibility of 2dDR-functionalized electrospun PCL grafts for promoting rapid endothelialization in small-diameter vascular graft applications. Future studies will focus on dynamic conditioning and in vivo validation to further assess translational potential.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Tissue Engineering and Regenerative Medicine · Silk-based biomaterials and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (87)
Show source-provided references
1. Heart disease and stroke statistics—2022 update: a report from the American heart association10.1161/CIR.0000000000001052 ↗
2. 2025 heart disease and stroke statistics: a report of US and global data from the American heart association10.1161/CIR.0000000000001303 ↗
3. The tissue-engineered vascular graft—past, present, and future10.1089/ten.teb.2015.0100 ↗
4. Considerations in the development of small-diameter vascular graft as an alternative for bypass and reconstructive surgeries: a review10.1007/s13239-020-00482-y ↗
5. Construction of vascular grafts based on tissue-engineered scaffolds10.1016/j.mtbio.2024.101336 ↗
6. An overview of small diameter vascular grafts: from materials to fabrication10.1039/D5MA00663E ↗
7. Reconstruction of vascular and urologic tubular grafts by tissue engineering10.3390/pr9030513 ↗
8. Future perspectives in small-diameter vascular graft engineering10.3390/bioengineering7040160 ↗
9. Synthetic and tissue-engineered vascular grafts: current status, emerging technologies, and clinical prospects10.31083/RCM45083 ↗
10. Blood vessel replacement: 50 years of development and tissue engineering paradigms in vascular surgery10.33549/physiolres.931918 ↗
11. Biomaterials for vascular tissue engineering10.2217/rme.09.77 ↗
12. Vascular damage and repair—are small-diameter vascular grafts still the “Holy Grail” of tissue engineering?10.33549/physiolres.935294 ↗
13. Manufacturing and validation of small-diameter vascular grafts: a mini review10.1016/j.isci.2024.109845 ↗
14. Technology insight: the evolution of tissue-engineered vascular grafts—from research to clinical practice10.1038/ncpcardio0930 ↗
15. Vascular grafts: technology success/technology failure10.34133/bmef.0003 ↗
16. Long-term experience in autologous in vitro endothelialization of infrainguinal ePTFE grafts10.1016/j.jvs.2008.08.101 ↗
17. Tissue engineering; current status & futuristic scope10.25122/jml-2019-0032 ↗
18. Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH1010.1007/s12013-011-9179-3 ↗
19. Vascular tissue engineering of small-diameter blood vessels: reviewing the electrospinning approach10.1002/term.1697 ↗
20. Factorial design optimization and in vivo feasibility of poly(ϵ-caprolactone)-micro- and nanofiber-based small diameter vascular grafts10.1002/jbm.a.32023 ↗
21. Long term performance of polycaprolactone vascular grafts in a rat abdominal aorta replacement model10.1016/j.biomaterials.2011.09.024 ↗
22. The return of a forgotten polymer—polycaprolactone in the 21st century10.1016/j.progpolymsci.2010.04.002 ↗
23. In vitro evaluation of electrospun nanofiber scaffolds for vascular graft application10.1002/jbm.a.31287 ↗
24. Electrospun fibre diameter and its effects on vascular smooth muscle cells10.1007/s10856-021-06605-8 ↗
25. Combining electrospun fiber mats and bioactive coatings for vascular graft prostheses10.1021/acs.biomac.6b01770 ↗
26. Vascular tissue engineering: polymers and methodologies for small caliber vascular grafts10.3389/fcvm.2020.592361 ↗
27. Vascularization in tissue engineering10.1016/j.tibtech.2008.04.009 ↗
28. Oxygen, a source of life and stress10.1016/j.febslet.2007.06.018 ↗
29. Targeting VEGF-induced vascular permeability10.1038/s44161-022-00066-0 ↗
30. Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives10.1038/s41392-025-02249-0 ↗
31. Developing wound dressings using 2-deoxy-D-ribose to induce angiogenesis as a backdoor route for stimulating the production of vascular endothelial growth factor10.3390/ijms222111437 ↗
32. 2-deoxy-d-ribose (2dDR) upregulates vascular endothelial growth factor (VEGF) and stimulates angiogenesis10.1016/j.mvr.2020.104035 ↗
33. A sweet way to increase the metabolic activity and migratory response of wound-related cells: deoxy-sugar incorporated natural polymeric fibres as a potential bioactive wound patch10.3906/biy-2108-27 ↗
34. Development of pro-angiogenic wound dressings from 2-deoxy-D-ribose (2dDR)-loaded decellularized plant leaves10.1007/s10853-023-09064-4 ↗
35. Developing affordable and accessible pro‐angiogenic wound dressings; incorporation of 2 deoxy D‐ribose (2dDR) into cotton fibres and wax‐coated cotton fibres10.1002/term.3072 ↗
36. Exploration of 2-Deoxy-D-ribose and 17β-estradiol as alternatives to exogenous VEGF to promote angiogenesis in tissue-engineered constructs10.2217/rme-2018-0068 ↗
37. Electrospinning: a versatile fabrication technique for nanofibrous membranes for use in desalination10.1016/B978-0-12-813926-4.00014-8 ↗
38. A novel bilayer polycaprolactone membrane for guided bone regeneration: combining electrospinning and emulsion templating10.3390/ma12162643 ↗
39. The drug-loaded electrospun poly(ϵ-caprolactone) mats for therapeutic application10.3390/nano11040922 ↗
40. Electrospinning of animal-free derived collagen-like protein: development and characterization of VECOLLAN®- nanofibers for biomedical applications10.1016/j.ijpx.2025.100398 ↗
41. Enhancing wound regeneration potential of fibroblasts using ascorbic acid-loaded decellularized baby spinach leaves10.1007/s00289-024-05185-1 ↗
42. Toxic or not toxic? The specifications of the standard ISO 10993–5 are not explicit enough to yield comparable results in the cytotoxicity assessment of an identical medical device10.3389/fmedt.2023.1195529 ↗
43. Decellularised extracellular matrix decorated PCL polyHIPE scaffolds for enhanced cellular activity, integration and angiogenesis10.1039/D1BM01262B ↗
44. Avoiding fusion of electrospun 3,3′,4,4′-biphenyltetracarboxylic dianhydride-4,4′-oxydianiline copolymer nanofibers during conversion to polyimide10.1016/j.polymer.2011.06.023 ↗
45. A comprehensive review summarizing the effect of electrospinning parameters and potential applications of nanofibers in biomedical and biotechnology10.1016/j.arabjc.2015.11.015 ↗
46. Morphological and mechanical properties of electrospun polycaprolactone scaffolds: effect of applied voltage10.3390/polym13040662 ↗
47. Effect of electrospinning parameters on the morphology of polyurethane/polycaprolactone fibers10.32508/stdj.v23i3.2410 ↗
48. Effects of electrostatic polarity and the types of electrical charging on electrospinning behavior10.1002/app.36680 ↗
49. Porous electrospun polycaprolactone fibers: effect of process parameters10.1002/polb.24090 ↗
50. Effect of electrospinning process parameters of polycaprolactone and nanohydroxyapatite nanocomposite nanofibers10.1177/0040517514566109 ↗
51. Control of inter-fiber fusing for nanofiber webs via electrospinning10.1177/155892501100600401 ↗
52. Electrospinning of biomedical nanofibers/nanomembranes: effects of process parameters10.3390/polym14183719 ↗
53. The effect of flow rate on morphology and deposition area of electrospun nylon 6 nanofiber10.1177/155892501200700414 ↗
54. An alginate-based tube gel delivering 2-deoxy-D-ribose for stimulation of wound healing10.1177/08853282231191218 ↗
55. Stimulation of hair regrowth in an animal model of androgenic alopecia using 2-deoxy-D-ribose10.3389/fphar.2024.1370833 ↗
56. Assessment of the angiogenic potential of 2-deoxy-D-ribose using a novel in vitro 3D dynamic model in comparison with established in vitro assays10.3389/fbioe.2019.00451 ↗
57. Electrospun nano- to microfiber fabrics made of biodegradable copolyesters: structural characteristics, mechanical properties and cell adhesion potential10.1016/j.biomaterials.2004.10.007 ↗
58. Effects of aligned and random fibers with different diameter on cell behaviors10.1016/j.colsurfb.2018.07.045 ↗
59. Growth behavior of endothelial cells according to electrospun poly(D,L-lactic-co-glycolic acid) fiber diameter as a tissue engineering scaffold10.1007/s13770-016-0053-7 ↗
60. Electrospun elastin-based vascular grafts10.1016/j.hlc.2008.05.042 ↗
61. Design of polycaprolactone vascular grafts10.1177/1528083714540701 ↗
62. The effect of thick fibers and large pores of electrospun poly(ϵ-caprolactone) vascular grafts on macrophage polarization and arterial regeneration10.1016/j.biomaterials.2014.03.078 ↗
63. Endothelialization of polycaprolactone vascular graft under the action of locally applied vascular endothelial growth factor10.1007/s10517-018-4144-4 ↗
64. Electrospun fibers for drug delivery after spinal cord injury and the effects of drug incorporation on fiber properties10.1159/000446621 ↗
65. Surface modification progress for PLGA-based cell scaffolds10.3390/polym16010165 ↗
66. Surface modification via alkali treatment and its effect on the physicochemical and biological properties of emulsion templated scaffolds10.1016/j.polymer.2025.128475 ↗
67. Effect of functionalization of the polycaprolactone film surface on the mechanical and biological properties of the film itself10.3390/polym14214654 ↗
68. Collagen surface modified poly(ϵ-caprolactone) scaffolds with improved hydrophilicity and cell adhesion properties10.1016/j.matlet.2014.06.132 ↗
69. Influence of the hydrophobic–hydrophilic nature of biomedical polymers and nanocomposites on in vitro biological development10.1002/mame.201700259 ↗
70. A spectrophotometric method for quantitative determination of xylose in fermentation medium10.1016/j.biombioe.2011.03.006 ↗
71. Material and structural characterization of human saphenous vein10.1016/0741-5214(90)90005-U ↗
72. Human tissue-engineered blood vessels for adult arterial revascularization10.1038/nm1364 ↗
73. Electrospinning of Biosyn®-based tubular conduits: structural, morphological, and mechanical characterizations10.1016/j.actbio.2011.01.008 ↗
74. Dynamic straining combined with fibrin gel cell seeding improves strength of tissue-engineered small-diameter vascular grafts10.1089/ten.tea.2008.0183 ↗
75. Fabrication of strong, bioactive vascular grafts with PCL/collagen and PCL/silica bilayers for small-diameter vascular applications10.1016/j.matdes.2019.108079 ↗
76. Small-diameter hybrid vascular grafts composed of polycaprolactone and polydioxanone fibers10.1038/s41598-017-03851-1 ↗
77. Fabrication of burst pressure competent vascular grafts via electrospinning: effects of microstructure10.1002/jbm.a.31926 ↗
78. Design of scaffolds for blood vessel tissue engineering using a multi-layering electrospinning technique10.1016/j.actbio.2005.06.006 ↗
79. Improving vascular grafts: the importance of mechanical and haemodynamic properties10.1002/(SICI)1096-9896(200002)190:3<292::AID-PATH528>3.0.CO;2-S ↗
80. Suture retention strength of P(LLA-CL) tissue-engineered vascular grafts10.1039/C9RA04529E ↗
81. Development of a composite vascular scaffolding system that withstands physiological vascular conditions10.1016/j.biomaterials.2008.03.032 ↗
82. Mechanical properties of completely autologous human tissue engineered blood vessels compared to human saphenous vein and mammary artery10.1016/j.biomaterials.2008.11.011 ↗
83. A compliant and biomimetic three-layered vascular graft for small blood vessels10.1088/1758-5090/aa6bae ↗
84. Cytotoxicity of polymers intended for the extrusion-based additive manufacturing of surgical guides10.1038/s41598-022-11426-y ↗
85. Enhanced vascularization in hybrid PCL/gelatin fibrous scaffolds with sustained release of VEGF10.1155/2015/865076 ↗
86. Investigation of cell adhesion and cell viability of the endothelial and fibroblast cells on electrospun PCL, PLGA and coaxial scaffolds for production of tissue engineered blood vessel10.3390/jfb13040282 ↗
87. Vascular tissue engineering: fabrication and characterization of acetylsalicylic acid‐loaded electrospun scaffolds coated with amniotic membrane lysate10.1002/jcp.28266 ↗